Home
Current projects
Methods for valuing health states
Blog
Disease Areas
Arthritis
Cancer
Dermatology
HIV
Obesity
Opthalmology
Publications
Papers
Presentations
Research methods
Economic evaluation
Epidemiology
Meta analysis
Other
Direct to consumer genetic tests
Value of research
Outcome measurement and valuation
Productivity
Year
2001
2004
2005
2006
2007
2008
2009
2010
Subscribe
Healthanomics
A collection of work and information about decision making in health
10 posts:
Impact of the recall period on measuring health utilities for acute events
28.12.2008
Tagged as:
Paper
More details →
Impact of the recall period on measuring health utilities for acute events
01.12.2008
Tagged as:
Paper
More details →
Economic Evaluations in Rheumatoid Arthritis: A Critical Review of Measures Used to Define Health States
01.12.2008
Tagged as:
Paper
More details →
Short-term influence of adalimumab on work productivity outcomes in patients with rheumatoid arthritis
01.09.2008
Tagged as:
Paper
More details →
Health state utility values: A description of their development and application for rheumatic diseases
01.07.2008
Tagged as:
Paper
More details →
A preliminary model-based assessment of the cost-utility of a screening programme for early age-related macular degeneration
28.06.2008
Tagged as:
Paper
More details →
A preliminary model-based assessment of the cost-utility of a screening programme for early age-related macular degeneration
01.06.2008
Tagged as:
Paper
More details →
Biologic Drugs for Rheumatoid Arthritis in the Medicare Program
01.04.2008
Tagged as:
Paper
More details →
The Validity and Responsiveness of Generic Utility Measures in Rheumatoid Arthritis: A Review
01.04.2008
Tagged as:
Paper
More details →
Infliximab, etanercept and adalimumab for the treatment of ankylosing spondylitis: cost-effectiveness evidence and NICE guidance
01.02.2008
Tagged as:
Paper
More details →
Display multiple categories by selecting below
Disease Areas
Arthritis
Cancer
Dermatology
HIV
Obesity
Opthalmology
Publications
Papers
Presentations
Research methods
Economic evaluation
Epidemiology
Meta analysis
Other
Outcome measurement and valuation
Productivity
Year
2001
2004
2005
2006
2007
2008
2009
2010
Most important contributions
Treatment of very early rheumatoid arthritis with symptomatic therapy, disease-modifying antirheumatic drugs, or biologic agents: a cost-effectiveness analysis
Impact of the recall period on measuring health utilities for acute events
Using mixed treatment comparisons and meta-regression to perform indirect comparisons to estimate the efficacy of biologic treatments in rheumatoid arthritis
Modelling the cost-effectiveness of etanercept in adults with rheumatoid arthritis in the UK
Using a discrete choice experiment to estimate societal health state utility values
Translator